Selective effects of D- and L-Govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia

Christopher C. Lapish, Kee Chan Ahn, R. Chambers, Donovan M. Ashby, Soyon Ahn, Anthony G. Phillips

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

There is a critical need to develop novel pharmacotherapeutics capable of addressing the positive, negative, and cognitive symptoms of schizophrenia. Building on recent studies with a racemic mixture of the synthetic tetrahydroprotoberberine, D,L-Govadine, we isolated the D- and L-stereoisomers and employed a battery of behavioral, neurochemical, and electrophysiological procedures to assess their individual therapeutic potential. Rodent models predictive of antipsychotic efficacy and those that model positive symptoms were employed and we found that L-Govadine, but not D-Govadine, improved these measures. Pretreatment with either stereoisomer during CS pre-exposure prevented the disruption of latent inhibition by amphetamine. Moreover, pretreatment with either stereoisomer also improved deficits in social interaction in the neonatal ventral hippocampal lesioned rat. Improved cognitive performance in two different prefrontal cortex-dependent tasks was observed with D-, but not L-Govadine, which strongly suggests that the D-steroisomer may be an effective cognitive enhancer. Alterations in dopamine efflux were also assessed and L-Govadine increased dopamine efflux in both the prefrontal cortex and nucleus accumbens. However, D-Govadine only increased dopamine efflux in the prefrontal cortex and not in the nucleus accumbens. Electrophysiological studies confirmed that L-Govadine is a DA-D2 antagonist, whereas D-Govadine shows no appreciable physiological effects at this receptor. Collectively these data show that L-Govadine performs well on measures predictive of antipsychotic efficacy and rodent models of positive symptoms through antagonism of DA-D2 receptors, whereas D-Govadine improves impairments in compromised memory function in delayed response tasks possibly through selective increases in DA efflux in the frontal cortex.

Original languageEnglish
Pages (from-to)1754-1762
Number of pages9
JournalNeuropsychopharmacology
Volume39
Issue number7
DOIs
StatePublished - 2014

Fingerprint

Neurobehavioral Manifestations
Schizophrenia
Stereoisomerism
Prefrontal Cortex
Dopamine
Nucleus Accumbens
Antipsychotic Agents
Rodentia
govadine
Nootropic Agents
Frontal Lobe
Amphetamine
Interpersonal Relations

Keywords

  • antipsychotic
  • cognitive enhancer
  • dopamine
  • microdialysis
  • neonatal ventral hippocampal lesioned rat
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology
  • Medicine(all)

Cite this

Selective effects of D- and L-Govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia. / Lapish, Christopher C.; Ahn, Kee Chan; Chambers, R.; Ashby, Donovan M.; Ahn, Soyon; Phillips, Anthony G.

In: Neuropsychopharmacology, Vol. 39, No. 7, 2014, p. 1754-1762.

Research output: Contribution to journalArticle

Lapish, Christopher C. ; Ahn, Kee Chan ; Chambers, R. ; Ashby, Donovan M. ; Ahn, Soyon ; Phillips, Anthony G. / Selective effects of D- and L-Govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia. In: Neuropsychopharmacology. 2014 ; Vol. 39, No. 7. pp. 1754-1762.
@article{004b794bf0dd4dfc80b0b4b14ecbe2be,
title = "Selective effects of D- and L-Govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia",
abstract = "There is a critical need to develop novel pharmacotherapeutics capable of addressing the positive, negative, and cognitive symptoms of schizophrenia. Building on recent studies with a racemic mixture of the synthetic tetrahydroprotoberberine, D,L-Govadine, we isolated the D- and L-stereoisomers and employed a battery of behavioral, neurochemical, and electrophysiological procedures to assess their individual therapeutic potential. Rodent models predictive of antipsychotic efficacy and those that model positive symptoms were employed and we found that L-Govadine, but not D-Govadine, improved these measures. Pretreatment with either stereoisomer during CS pre-exposure prevented the disruption of latent inhibition by amphetamine. Moreover, pretreatment with either stereoisomer also improved deficits in social interaction in the neonatal ventral hippocampal lesioned rat. Improved cognitive performance in two different prefrontal cortex-dependent tasks was observed with D-, but not L-Govadine, which strongly suggests that the D-steroisomer may be an effective cognitive enhancer. Alterations in dopamine efflux were also assessed and L-Govadine increased dopamine efflux in both the prefrontal cortex and nucleus accumbens. However, D-Govadine only increased dopamine efflux in the prefrontal cortex and not in the nucleus accumbens. Electrophysiological studies confirmed that L-Govadine is a DA-D2 antagonist, whereas D-Govadine shows no appreciable physiological effects at this receptor. Collectively these data show that L-Govadine performs well on measures predictive of antipsychotic efficacy and rodent models of positive symptoms through antagonism of DA-D2 receptors, whereas D-Govadine improves impairments in compromised memory function in delayed response tasks possibly through selective increases in DA efflux in the frontal cortex.",
keywords = "antipsychotic, cognitive enhancer, dopamine, microdialysis, neonatal ventral hippocampal lesioned rat, Schizophrenia",
author = "Lapish, {Christopher C.} and Ahn, {Kee Chan} and R. Chambers and Ashby, {Donovan M.} and Soyon Ahn and Phillips, {Anthony G.}",
year = "2014",
doi = "10.1038/npp.2014.23",
language = "English",
volume = "39",
pages = "1754--1762",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Selective effects of D- and L-Govadine in preclinical tests of positive, negative, and cognitive symptoms of schizophrenia

AU - Lapish, Christopher C.

AU - Ahn, Kee Chan

AU - Chambers, R.

AU - Ashby, Donovan M.

AU - Ahn, Soyon

AU - Phillips, Anthony G.

PY - 2014

Y1 - 2014

N2 - There is a critical need to develop novel pharmacotherapeutics capable of addressing the positive, negative, and cognitive symptoms of schizophrenia. Building on recent studies with a racemic mixture of the synthetic tetrahydroprotoberberine, D,L-Govadine, we isolated the D- and L-stereoisomers and employed a battery of behavioral, neurochemical, and electrophysiological procedures to assess their individual therapeutic potential. Rodent models predictive of antipsychotic efficacy and those that model positive symptoms were employed and we found that L-Govadine, but not D-Govadine, improved these measures. Pretreatment with either stereoisomer during CS pre-exposure prevented the disruption of latent inhibition by amphetamine. Moreover, pretreatment with either stereoisomer also improved deficits in social interaction in the neonatal ventral hippocampal lesioned rat. Improved cognitive performance in two different prefrontal cortex-dependent tasks was observed with D-, but not L-Govadine, which strongly suggests that the D-steroisomer may be an effective cognitive enhancer. Alterations in dopamine efflux were also assessed and L-Govadine increased dopamine efflux in both the prefrontal cortex and nucleus accumbens. However, D-Govadine only increased dopamine efflux in the prefrontal cortex and not in the nucleus accumbens. Electrophysiological studies confirmed that L-Govadine is a DA-D2 antagonist, whereas D-Govadine shows no appreciable physiological effects at this receptor. Collectively these data show that L-Govadine performs well on measures predictive of antipsychotic efficacy and rodent models of positive symptoms through antagonism of DA-D2 receptors, whereas D-Govadine improves impairments in compromised memory function in delayed response tasks possibly through selective increases in DA efflux in the frontal cortex.

AB - There is a critical need to develop novel pharmacotherapeutics capable of addressing the positive, negative, and cognitive symptoms of schizophrenia. Building on recent studies with a racemic mixture of the synthetic tetrahydroprotoberberine, D,L-Govadine, we isolated the D- and L-stereoisomers and employed a battery of behavioral, neurochemical, and electrophysiological procedures to assess their individual therapeutic potential. Rodent models predictive of antipsychotic efficacy and those that model positive symptoms were employed and we found that L-Govadine, but not D-Govadine, improved these measures. Pretreatment with either stereoisomer during CS pre-exposure prevented the disruption of latent inhibition by amphetamine. Moreover, pretreatment with either stereoisomer also improved deficits in social interaction in the neonatal ventral hippocampal lesioned rat. Improved cognitive performance in two different prefrontal cortex-dependent tasks was observed with D-, but not L-Govadine, which strongly suggests that the D-steroisomer may be an effective cognitive enhancer. Alterations in dopamine efflux were also assessed and L-Govadine increased dopamine efflux in both the prefrontal cortex and nucleus accumbens. However, D-Govadine only increased dopamine efflux in the prefrontal cortex and not in the nucleus accumbens. Electrophysiological studies confirmed that L-Govadine is a DA-D2 antagonist, whereas D-Govadine shows no appreciable physiological effects at this receptor. Collectively these data show that L-Govadine performs well on measures predictive of antipsychotic efficacy and rodent models of positive symptoms through antagonism of DA-D2 receptors, whereas D-Govadine improves impairments in compromised memory function in delayed response tasks possibly through selective increases in DA efflux in the frontal cortex.

KW - antipsychotic

KW - cognitive enhancer

KW - dopamine

KW - microdialysis

KW - neonatal ventral hippocampal lesioned rat

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=84900551564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900551564&partnerID=8YFLogxK

U2 - 10.1038/npp.2014.23

DO - 10.1038/npp.2014.23

M3 - Article

C2 - 24476944

AN - SCOPUS:84900551564

VL - 39

SP - 1754

EP - 1762

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 7

ER -